EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)VergleichsstudieMultizentrische Studie

Gemcitabine/nab‐paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma

Xin An iD, Cong Xue, Meiting Chen, Mengqian Ni, Huali Ma, Li Tian, Riqing Huang, Xiangdong Li, Yunlin Ye iD, Tao Qin, Pei Dong, Zhiyong Li iD und 5 weitere

BJU International · 2024

DOI: 10.1111/bju.16241 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift BJU International, 2024. Verfasst von Xin An und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-se…. Hauptthemen laut MEDLINE: Gemcitabine, Deoxycytidine, Paclitaxel, Carboplatin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Sun Yat-sen University Clinical Research 5010 Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare in a phase III trial the efficacy and safety of nanoparticle albumin‐bound (nab)‐paclitaxel plus gemcitabine (GA) with that of carboplatin plus gemcitabine (GCb) as a first‐line treatment for patients with cisplatin‐ineligible metastatic urothelial cancer (mUC). Patients and Methods Treatment‐naive, cisplatin‐ineligible patients with mUC were assigned randomly to either the GA (both nab‐paclitaxel 125 mg/m 2 and gemcitabine 1000 mg/m 2 on Days 1 and 8, every 21 days) or GCb group (carboplatin area under the free carboplatin plasma concentration versus time curve of 4.5 on Day 1, gemcitabine 1000 mg/m 2 on Days 1 and 8, every 21 days). The primary endpoint was progression‐free survival (PFS). Secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), safety, and patient‐reported outcomes (PROs).

Results

The trial was terminated early because of slow accrual after 54 patients were enrolled: 26 in in the GA group and 28 in the GCb groups. The median PFS was 6.7 vs 5.9 months for the GA and GCb groups, respectively ( P = 0.248). The median OS time was 12.1 vs 10.7 months for the GA and GCb groups, respectively ( P = 0.837). The ORR and DCR were 40% vs 46.4% ( P = 0.637) and 72% vs 68% ( P = 0.188) in the GA and GCb groups, respectively. Patients treated with GA showed significantly lower incidence of Grade 3–4 thrombocytopenia and does reduction and delay. Although peripheral sensory neuropathy was higher in the GA arm, no Grade 3 neuropathy occurred. There was no difference in the PROs between the two groups.

Conclusion

While not powered for comparison, first‐line GA showed similar efficacy and better tolerability and might be considered a rational alternative to GCb.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GemcitabineDeoxycytidinePaclitaxelCarboplatinAntineoplastic Combined Chemotherapy ProtocolsAlbuminsHumansMaleAgedFemaleMiddle AgedCarcinoma, Transitional CellAged, 80 and overUrologic NeoplasmsTreatment OutcomeUrinary Bladder NeoplasmsProgression-Free Survival

Stichwörter der Autor:innen

carboplatincisplatin‐ineligiblefirst‐linegemcitabinemetastatic urothelial carcinomanab‐paclitaxel

Substanzen

GemcitabineDeoxycytidinePaclitaxelCarboplatin130-nm albumin-bound paclitaxelAlbumins

Autor:innen und Institutionen

  • Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Radiology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Urology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Medical Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.

ORCID-Profile: Xin An, Yunlin Ye, Zhiyong Li, Zhuowei Liu

Förderung

  • Sun Yat-sen University Clinical Research 5010 Program

Zitieren

APA

An, X., Xue, C., Chen, M., Ni, M., Ma, H., Tian, L., Huang, R., Li, X., Ye, Y., Qin, T., Dong, P., Li, Z., Peng, J., Yao, K., Zhou, F., Liu, Z., & Shi, Y. (2024). Gemcitabine/nab‐paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma. BJU International. https://doi.org/10.1111/bju.16241

Vancouver

An X, Xue C, Chen M, Ni M, Ma H, Tian L, et al. Gemcitabine/nab‐paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma. BJU International. 2024. doi:10.1111/bju.16241

BibTeX
@article{An2024,
  author = {An, Xin and Xue, Cong and Chen, Meiting and Ni, Mengqian and Ma, Huali and Tian, Li and Huang, Riqing and Li, Xiangdong and Ye, Yunlin and Qin, Tao and Dong, Pei and Li, Zhiyong and Peng, Jing and Yao, Kai and Zhou, Fangjian and Liu, Zhuowei and Shi, Yanxia},
  title = {Gemcitabine/nab‐paclitaxel vs gemcitabine/carboplatin for advanced urothelial carcinoma},
  journal = {BJU International},
  year = {2024},
  doi = {10.1111/bju.16241}
}
Kostenlos starten →